GSK stock heads into the open after a 4.08 percent gain

At the close on September 16, 2026, GSK stock finished at 1,759,000.00 KRW on Korea Exchange with a 4.08 percent rise. It also outpaced the venue's move in the last session, and GSK agreed on September 16 to acquire a Chimagen cancer program.

GSK stock finished at 1,759,000.00 KRW on Korea Exchange on September 16, 2026, up 4.08 percent from the prior close. The move came after the market reacted to a GSK agreement to acquire a Chimagen trispecific T cell engager program for multiple myeloma.

September 16, 2026 in numbers

GSK plc (ISIN GB0009252882) traded between 1,759,000.00 KRW and 1,759,000.00 KRW in the last session, with volume of 937B shares. That close matched the session high and sat above the prior close by 4.08 percent, while the reference index also ended higher. The session figures point to a firm close rather than a narrow fade.

As Reuters reported on September 16, GSK agreed to acquire the program from Chimagen Biosciences, with total potential value of up to USD 750 million. The deal gave the shares a clear session anchor.

Today

As Reuters reported on September 16, the broader market also turned on the Federal Reserve's rate path, which can still shape large pharmaceutical shares today. The Chimagen transaction remains the main company-specific item in focus this morning.